Akademik Veri Yönetim Sistemi
Endokrynologia Polska, cilt.77, sa.2, ss.112-119, 2026 (SCI-Expanded, Scopus)
Introduction: Prolactin has been shown to play an important role in the regulation of glucose metabolism. The present study aimed to evaluate incretin hormones in patients with prolactinoma. Material and methods: The study included 13 patients with prolactinoma without a history of diabetes and in 13 healthy volunteers. All participants underwent a 75-g oral glucose tolerance test (OGTT). Serum glucose, insulin, glucagon-like peptide-1 (GLP-1), and glucose-dependent insulinotropic polypeptide (GIP) were measured at 0, 30, 60, 90, and 120 minutes. Results: Serum glucose and insulin levels at baseline and during the OGTT were similar in both groups (p > 0.05). GLP-1 levels, including baseline values, area under the curve (AUC), and all time points during OGTT, were also comparable between the groups (p > 0.05). In contrast, baseline GIP (p = 0.024), AUC (p = 0.011), and GIP levels at 30, 90, and 120 minutes were significantly lower in patients with prolactinoma (p = 0.006, p = 0.015, and p = 0.035, respectively). Conclusions: These findings suggest that incretins may play a role in the mechanisms underlying glucose metabolism disorders in patients with hyperprolactinemia due to prolactinoma. Larger studies are needed to confirm this potential association.